BRACCO Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRACCO, and when can generic versions of BRACCO drugs launch?
BRACCO has forty approved drugs.
There are three US patents protecting BRACCO drugs.
There are thirty-seven patent family members on BRACCO drugs in twelve countries and seventy-four supplementary protection certificates in eight countries.
Summary for BRACCO
| International Patents: | 37 |
| US Patents: | 3 |
| Tradenames: | 64 |
| Ingredients: | 32 |
| NDAs: | 40 |
Drugs and US Patents for BRACCO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | MULTIHANCE MULTIPACK | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021358-001 | Nov 23, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bracco | MULTIHANCE | gadobenate dimeglumine | INJECTABLE;INTRAVENOUS | 021357-002 | Nov 23, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Bracco | VARIBAR THIN LIQUID | barium sulfate | FOR SUSPENSION;ORAL | 208036-004 | Apr 30, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BRACCO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | ISOVUE-370 | iopamidol | INJECTABLE;INJECTION | 020327-004 | Oct 12, 1994 | 4,001,323 | ⤷ Sign Up |
| Bracco | ISOVUE-300 | iopamidol | INJECTABLE;INJECTION | 020327-003 | Oct 12, 1994 | 4,001,323 | ⤷ Sign Up |
| Bracco | CARDIOGEN-82 | rubidium chloride rb-82 | INJECTABLE;INJECTION | 019414-001 | Dec 29, 1989 | 4,562,829 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BRACCO Drugs
Supplementary Protection Certificates for BRACCO Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1856135 | CR 2020 00018 | Denmark | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| 2666774 | CA 2020 00037 | Denmark | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 2203431 | 15C0013 | France | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
